Selank — reference
A synthetic analogue of tuftsin, used in Russia as an anxiolytic without the sedation or dependence of benzodiazepines.
Regulatory status
Not FDA-Approved. Approved in Russia; not FDA-approved in the US.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~20 minutes. Similar evidence base/limitations as Semax.
This figure is tagged Limited data in our evidence system. The available data does not support a confident single figure, so this entry is flagged accordingly. Read any curve built from it as illustrative only. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Selank FDA-approved?
What is the half-life of Selank?
How reliable is that half-life figure?
What cautions are associated with Selank?
Does Peptide Plug publish dosing for Selank?
Does Peptide Plug sell Selank?
Related tools
Free, no account required.